Citi analysts increased Sanofi's price target due to recent performance but expressed concerns about its medicine pipeline and future competition for Dupixent. This indicates a mixed outlook for Sanofi, with short-term positive sentiment tempered by long-term strategic challenges.
Citi analysts raised Sanofi's price target from 78 to 93 euros, signaling a positive short-term outlook based on recent performance. However, they highlighted significant long-term risks, specifically Sanofi's medicine pipeline requiring M&A to address deficiencies and the looming competition for its blockbuster drug Dupixent from AstraZeneca, Pfizer, and AbbVie/Apogee. This creates a nuanced situation for traders: while the price target increase might suggest a buy, the underlying pipeline weakness and future competitive threats could cap long-term upside. The projected deceleration of Dupixent's growth from 32% in 2026 to 12% in 2027 is a key concern, indicating a potential revenue slowdown for Sanofi in the medium term.